GlassScriptPhysician profile
Steven Peikin
NPI 1770655060
$1,515.97
in general payments reported to CMS, 2019-2025
20 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $335 · 2021: $136 · 2022: $14.78 · 2024: $369 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $313.96 | 2019-2020 | |
| Gilead Sciences, INC. | $187.21 | 2021-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $162.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Fujifilm Healthcare Americas Corporation | $144.78 | 2024-2025 | Fujifilm |
| Intercept Pharmaceuticals, INC. | $124.89 | 2020 | |
| Olympus America INC. | $99.98 | 2019 | |
| Abbvie INC. | $73.16 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.49 | 2020-2021 | |
| Erbe USA INC | $70.00 | 2024 | |
| Janssen Biotech, INC. | $56.29 | 2024-2025 | Stelara, Simponi, Tremfya |
| Ambu INC. | $39.49 | 2021 | |
| Lilly USA, LLC | $34.96 | 2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $29.61 | 2019-2024 | Eohilia |
| Ardelyx, INC. | $21.88 | 2025 | Ibsrela |
| Novo Nordisk INC | $16.80 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $15.63 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.78 | 2022 | |
| Redhill Biopharma INC. | $14.42 | 2021 | |
| Shionogi INC | $12.76 | 2019 | |
| Braintree Laboratories, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Peikin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.